Clinical Trial

ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Exploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overall clinical cure rate to more than 50% without screening specific advantageous groups.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-05.
Trial Details
NCT Number NCT07573943
Lead Sponsor The Second Affiliated Hospital of Chongqing Medical University
Collaborators: First Affiliated Hospital of Chongqing Medical University, Three Gorges Hospital of Chongqing University, Guizhou Provincial People's Hospital
Conditions Chronic Hepatitis b
Enrollment 150 participants
Start Date 2024-05-21
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-07